Top Markets
Coin of the day
Biocure Technology Inc. Biocure Technology Inc.

Biocure Technology Inc.

CURE
Rang in aandelen #39915
Biocure Technology Inc., operating with its subsidiary, focuses on the creation... Biocure Technology Inc., operating with its subsidiary, focuses on the creation and market introduction of biopharmaceutical innovations, particularly those involving recombinant technologies and ranibizumab. The company's current development pipeline includes: Interferons-ß, aimed at treating multiple sclerosis. Ranibizumab, a monoclonal antibody fragment designed to address macular degeneration and a related eye condition known as macular edema. Filgrastim, which targets neutropenia – a deficiency of white blood cells that can arise from cancer, bone marrow transplants, chemotherapy, or other medical issues. Additionally, Biocure is conducting research and development into several promising areas: CAR T-cell therapy, which works by identifying and eradicating cancer cells. A vaccine against foot and mouth disease. Various products for promoting hair growth. The firm was established in 2005 and its corporate headquarters are located in Vancouver, Canada.
Aandeelprijs
$0.00366968
Laatst gesynchroniseerd: 2024-07-12
Marktkapitalisatie
$299.46K
Verandering (1 dag)
-66.77%
Verandering (1 jaar)
0.00%
Land
CA
Handel Biocure Technology Inc. (CURE)

Categorie

EPS voor Biocure Technology Inc. (CURE)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van Biocure Technology Inc. is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van Biocure Technology Inc. van 2026 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
EPS van vergelijkbare bedrijven of concurrenten